Society of Urologic Oncology - MANAGEMENT AND OUTCOMES OF PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER: EVOLUTION OF THE UNIVERSITY OF SOUTHERN CALIFORNIA EXPERIENCE OVER 3,347 CASES
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
a Kaplan–Meier survival curve with a median follow-up time of... | Download Scientific Diagram
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Survival Analysis
Kaplan-Meier plot of overall survival. Median follow-up was 21.3 months... | Download Scientific Diagram
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
Efficacy of KISQALI® (ribociclib) + AI in 1L Postmenopausal | HCP
How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine - ScienceDirect
Survival Analysis in R
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
TIBSOVO® (ivosidenib tablets) an IDH1 Inhibitor
Kaplan-Meier survival analysis
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Opdualag™ (nivolumab and relatlimab-rmbw) Efficacy in Melanoma
GraphPad Prism 10 Statistics Guide - Determining the median followup time
A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports
Laying the Foundation Towards Long-Term Survival in Patients with High-Risk Acute Myeloid Leukaemia - European Medical Journal
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum
a Kaplan?Meier relapse-free survival (median follow-up time 42 months)... | Download Scientific Diagram
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors | Scientific Reports
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Survival Analysis
Let's Flip: An Approach to Understand Median Follow-up by the Reverse Kaplan-Meier Estimator from a Statistical Programmer's
The overall survival did not reach median. The median progression free... | Download Scientific Diagram
